Seres Therapeutics (NASDAQ:MCRB – Get Free Report) and Cue Biopharma (NASDAQ:CUE – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.
Risk and Volatility
Seres Therapeutics has a beta of 0.44, suggesting that its stock price is 56% less volatile than the S&P 500. Comparatively, Cue Biopharma has a beta of 2.79, suggesting that its stock price is 179% more volatile than the S&P 500.
Profitability
This table compares Seres Therapeutics and Cue Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Seres Therapeutics | -2,209.55% | -194.42% | -58.15% |
| Cue Biopharma | -579.95% | -620.87% | -322.13% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Seres Therapeutics | 1 | 1 | 2 | 0 | 2.25 |
| Cue Biopharma | 1 | 1 | 1 | 0 | 2.00 |
Seres Therapeutics presently has a consensus target price of $17.00, indicating a potential upside of 1,261.09%. Cue Biopharma has a consensus target price of $83.00, indicating a potential upside of 1,900.00%. Given Cue Biopharma’s higher probable upside, analysts clearly believe Cue Biopharma is more favorable than Seres Therapeutics.
Valuation and Earnings
This table compares Seres Therapeutics and Cue Biopharma”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Seres Therapeutics | $790,000.00 | 16.11 | $5.70 million | ($5.00) | -0.25 |
| Cue Biopharma | $27.47 million | 1.10 | -$26.60 million | ($29.66) | -0.14 |
Seres Therapeutics has higher earnings, but lower revenue than Cue Biopharma. Seres Therapeutics is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
59.3% of Seres Therapeutics shares are held by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are held by institutional investors. 5.2% of Seres Therapeutics shares are held by insiders. Comparatively, 14.6% of Cue Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Seres Therapeutics beats Cue Biopharma on 8 of the 14 factors compared between the two stocks.
About Seres Therapeutics
Seres Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing microbiome-based medicines. Its approach uses live biotherapeutic products designed to influence the gut microbiome and address conditions including infections and complications associated with impaired immune function. The company developed VOWST, an oral microbiota-based therapy approved in the United States to prevent recurrent Clostridioides difficile infection in adults after antibacterial treatment.
About Cue Biopharma
Cue Biopharma, Inc. is a biotechnology company developing biologic medicines designed to selectively engage and modulate T cells. Its Immuno-STAT platform is intended to direct immune activity toward disease-specific targets, with potential applications in cancer and autoimmune disorders. The company’s research has included cancer candidates such as CUE-101, designed to target HPV16-positive cancers, and CUE-102, developed to target cancers expressing the WT1 protein. Cue Biopharma has also pursued programs intended to influence immune responses in autoimmune disease.
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
